Is Fractyl Health, Inc. (GUTS) a Buy, Sell, or Hold?
Fractyl Health, Inc.
NASDAQ:GUTS
$0.8 USD
$0.04 (5.03%)
- Volume
- 1.38M
- Average Volume
- 1.84M
- Market Capitalization
- $57.76M
- P/E Ratio
- -0.46
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $2.45
- Year Low
- $0.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.28
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Harith Rajagopalan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GUTS |
| CUSIP | 35168W103 |
| CIK | 0001572616 |
| Web | https://fractyl.com |
| Phone | 781-902-8800 |
| Currency | USD |
| Employees | 100 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.84 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.28 |
| Quick Ratio | 4.28 |
| Cash Ratio | 4.10 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.16 |
| Price / Cash Flow | -0.66 |
| Price / Book | 2.84 |
Price Target and Rating
| Average Stock Price Forecast | $2.00 |
| High Stock Price Forecast | $2.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | -60.00% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.86 |
| Trailing P/E Ratio | -0.46 |
| PEG Ratio | 0.12 |
| P/E Growth | 0.12 |
| Net Income | $-140.95M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -4573.89% |
| Return on Assets | -108.67% |
Financials Score
| AltmanZ Score | -10.26 |
| Piotroski Score | 2.00 |
| Working Capital | 50.51M |
| Total Assets | 99.38M |
| Ebit | -108M |
| Market Cap | 54.99M |
| Total Liabilities | 78.01M |
Poll Results
About Fractyl Health, Inc. (NASDAQ:GUTS) Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headqu ... artered in Burlington, Massachusetts.
2026-07-15 06:00:00
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026 Company to host investor webcast today at 8:00 a.m. ET BURLINGTON, Mass.
2026-06-04 07:00:00
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
2026-06-01 07:00:00
BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced the appointment of Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy.
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2026-05-14 16:40:43
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
2026-05-12 21:50:45
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health Q1 Earnings Call Highlights
2026-05-12 20:25:40
Fractyl Health NASDAQ: GUTS said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments during the company's first-quarter 2026 earnings call.
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
2026-05-12 16:05:00
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month randomized data from the REMAIN-1 Pivotal Cohort and late Q4 2026 timing for potential FDA De Novo marketing application submission in post-GLP-1 weight maintenance reaffirmed Clinical Trial Application authorization of RJVA-001 first-in-human study in the Netherlands for T2D; first-in-human dosing anticipated in second half of 2026 reiterated Cash runway guidance into early 2027, beyond anticipated Pivotal data readout reiterated Conference call today at 4:30 p.m. ET BURLINGTON, Mass.
2026-05-11 07:00:00
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2 diabetes
Frequently Asked Questions
-
What is the current Fractyl Health, Inc. (GUTS) stock price?
-
Fractyl Health, Inc.(NASDAQ:GUTS) stock price is $0.8 in the last trading session. During the trading session, GUTS stock reached the peak price of $2.445 while $0.377 was the lowest point it dropped to. The percentage change in GUTS stock occurred in the recent session was 5.03% while the dollar amount for the price change in GUTS stock was $0.04.
-
GUTS's industry and sector of operation?
-
The NASDAQ listed GUTS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GUTS?
-
Harith Rajagopalan | Co-Founder, Chief Executive Officer & Director
Brian Luque | Head of Investor Relations & Corporate Development
Mike Zumdahl | Senior Vice President of Market Access & Commercial Strategy
Jon Fitzgerald | Senior Vice President of Regulatory, Quality & Clinical
Lara Smith Weber | Chief Financial Officer & Treasurer -
How many employees does GUTS have?
-
Number of GUTS employees currently stands at 100. GUTS operates from 3 Van de Graaff Drive, Burlington, MA 01803, US.
-
Link for GUTS official website?
-
Official Website of GUTS is: https://fractyl.com
-
How do I contact GUTS?
-
GUTS could be contacted at phone #781-902-8800 and can also be accessed through its website. GUTS operates from 3 Van de Graaff Drive, Burlington, MA 01803, US.
-
How many shares of GUTS are traded daily?
-
The average number of GUTS shares traded daily for last 3 months was 1.84M.
-
What is the market cap of GUTS currently?
-
The market value of GUTS currently stands at $57.76M with its latest stock price at $0.8